Nurix Therapeutics (NRIX)’ treatment of Waldenstrom macroglobulinemia was granted FDA orphan designation, according to a post on the agency’s ...
Nurix Therapeutics, Inc. is a San Francisco based early clinical-stage biotechnology concern focused on leveraging its expertise in cellular protein modulation to develop therapies against ...
The fireside chat will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event. About Nurix ...
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) is expected to announce its earnings results on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.67 ...
Nurix Therapeutics, Inc. SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development ...
Zacks Investment Research on MSN1d
Zymeworks (ZYME) Soars 5.4%: Is Further Upside Left in the Stock?Zymeworks Inc. (ZYME) shares soared 5.4% in the last trading session to close at $11.70. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...
SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback